Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

Zhien Zhou  
Peking Union Medical College Hospital

Meiting He  
Capital Medical University Affiliated Anzhen Hospital

Yi Zhou  
Peking Union Medical College Hospital

Weigang Yan (✉ pumchywg@sina.com)  
Peking Union Medical College Hospital  https://orcid.org/0000-0002-7406-4694

Xingcheng Wu  
Peking Union Medical College Hospital

Zhibo Zheng  
Peking Union Medical College Hospital

Fuquan Zhang  
Peking Union Medical College Hospital

Zhigang Ji  
Peking Union Medical College Hospital

Hanzhong Li  
Peking Union Medical College Hospital

Research

Keywords: Prostatic neoplasms; Low-dose-rate brachytherapy; Radical prostatectomy, Treatment outcomes, Comparative effectiveness

DOI: https://doi.org/10.21203/rs.3.rs-29556/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) are two widely used treatment options for patients with intermediate-risk prostate cancer (IRPC). However, which one is better remains controversial. Therefore, the purpose of this study was to compare the efficacy of RP vs LDR for patients with IRPC.

**Methods:** A retrospective analysis was performed on 361 IRPC patients who underwent treatment from January 2010 and August 2017. 160 underwent RP and 201 underwent LDR using Iodine-125. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for LDR as nadir PSA level + 2 ng/ml. The log-rank test compared biochemical relapse-free survival (bRFS) between the two modalities, and Cox regression identified factors associated with bRFS.

**Results:** Median follow-up was 54 months for RP and 69 months for LDR. The 5-and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively, P=0.003. There were no significant differences in terms of clinical relapse-free survival (cRFS), cancer-specific survival (CSS) or overall survival (OS) between the two groups.

**Conclusion:** LDR is a reasonable treatment option for IRPC patients, yielding improved bRFS and equivalent rates of cRFS, CSS and OS compared with RP.

Background

Prostate cancer (Pca) is the second most common cause of cancer-related death in U.S. men in 2018(1). Although the incidence of Pca in China is lower than in western countries, it keeps growing in recent years due to aging and the improvements in healthcare (2). Radical prostatectomy (RP), low-dose-rate brachytherapy (LDR), and external beam radiation therapy (EBRT) are the three major definitive treatment options for localized prostate cancer. Established clinical guidelines recommend that treatment decisions should be made based on tumor features, baseline prostate specific antigen (PSA) levels, patient age, comorbidity, life expectancy, and quality of life (3-5). However, which of these treatments is the best for patients with localized prostate cancer remains a subject of debate.

LDR has shown impressive 10-year results (6, 7). However, most of these patients were low risk, for which there is no significant benefit to local therapy (8). The National Comprehensive Cancer Network (NCCN) guidelines recommend local therapy for intermediate-risk prostate cancer (IRPC) (5). Randomized trials of IRPC patients treated with RP vs LDR have not been done. Thus, there is no clear evidence to inform clinical decisions regarding adequate treatment for IRPC patients. Our aim was to perform a retrospective study of IRPC, comparing the long term of outcomes of RP vs LDR at a single institution in China. We sought to identify variables that may predict differences in biochemical control, including treatment modality as a variable, using the most recent consensus definitions of biochemical failure (BF).

Materials And Methods
1 Patients

A group of 361 consecutive IRPC patients treated with curative intent between January 2010 and August 2017 at the Peking Union Medical College Hospital were identified. Of these patients, 160 (44.3%) underwent RP and 201 (55.7%) received LDR. All patients had biopsy-proven prostate adenocarcinoma, and all external pathological specimens were reviewed by pathologists in our institution. All patients were categorized according to the US NCCN risk classification criteria(5), which define IRPC by clinical stage T2b-c, Gleason score (GS) 3 + 4 (group 2) or 4 + 3 (group 3), and/or initial PSA (iPSA) of 10.1-20.0 ng/ml. Percentage positive biopsy cores (PPBC) >50% was calculated from the pathology report. Favorable IRPC was described as 1 intermediate adverse risk factor, such as GS 3 + 4 (group 2), iPSA 10.1-20.0 ng/ml, or clinical stage T2b-c. Patients with multiple intermediate adverse risk factors, which included PPBC >50%, or any IRPC with GS 4 + 3 (group 3), were classified as unfavorable IRPC (9).

The following information was evaluated for all patients: medical history, physical examination, digital rectal examination and iPSA (serum PSA prior to treatment). Clinical staging was based on digital rectal examination and, when clinically indicated, chest radiography, bone scintigraphy, CT-scan and/or magnetic resonance imaging of the pelvis.

2 Treatments

RP was performed by a pure laparoscopic prostatectomy, with the extent of pelvic lymph node dissection being based upon the risk category of the patient. The procedure was performed according to the technique described by Walsh (10). The vesico-urethral anastomosis was made with a running suture with Y604 (Ethieon, USA).

LDR was planned so that the prostate and proximal seminal vesicles received 145 Gy with a 5-mm margin laterally, anteriorly, and inferiorly (11). No margin was planned superiorly (bladder) and posteriorly (rectum). \(^{125}\)I seeds were accurately introduced into preplanned positions by a brachytherapy stepping unit MICK200 (Computerized Medical Systems, Inc, St. Louis, MO, USA) using a standard 0.5 cm brachytherapy template placed over the perineum. One week after implantation, dosimetric analysis was performed by CT scan, and the D90 (defined as the minimum dose covering 90% of the prostate) was obtained for each patient.

3 Follow-up and study endpoints

Time zero was the day of RP or LDR. Patients were followed up monthly during the first 3 months and at 3-month intervals thereafter. If PSA level was stable, routine follow-up was scheduled every 6 months after 2 years of treatment. The treatment outcomes were assessed in terms of biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), and cancer-specific survival (CSS), and overall survival (OS). BF was defined as a PSA value ≥ 0.2 ng/mL for patients who underwent RP (12) and an increase of 2 ng/mL or > nadir PSA value (Phoenix definition) (13) for patients receiving LDR. If a patient received salvage radiotherapy or endocrine therapy, the patient was counted as having experienced a BF.
Clinical relapse was defined as metastases identified by medical imaging, with or without localizing symptoms, or as biopsy-proven local recurrence. Cancer-specific mortality was defined as mortality due to Pca, as noted on the death certificate alongside the biochemical and clinical information, or the presence of uncontrolled metastatic disease at the time the patient succumbed.

4 Statistical analysis

Factors considered to influence the endpoint were recorded for baseline analysis. Student’s t-test was used to evaluate differences in the mean of continuous variables. A χ² test was performed to compare ratios and Mann-Whitney U test to compare medians. Differences between two survival curves were evaluated by log-rank tests. Cox proportional-hazard models were constructed to identify factors associated with bRFS. Statistical analyses were performed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA). P <0.05 was considered to be statistically significant in this study.

Results

Patient Characteristics

A total of 361 patients were included in the present study, comprising 201 LDR patients (55.7%) and 160 RP patients (44.3%). The median follow-up for RP and LDR was 54 and 69 months, respectively. Patients treated with LDR were older, experienced a longer follow-up time and had a higher preponderance of combined ADT treatment and a lower proportion of clinical stage T2b-c. Table 1 presents a full comparison of pretreatment characteristics between the LDR and PR groups. The mean D90 for the LDR group was 144 Gy (1 standard deviation = 20.58Gy). For RP, positive margins were found in 55 (34.4%) patients. Extracapsular extension was found in 31 (19.3%), seminal vesicle invasion in 18 (11.3%), resulting in 42 (26.3%) RP patients upstaged to pathologic T3. Neoadjuvant or adjuvant androgen deprivation therapy (ADT) was given 31.2% for RP vs 94.5% for LDR, P<0.001. Supplemental EBRT were used in 15 patients (9.4%) in the RP group and 5 patients (2.5%) in the LDR group, respectively.

Main Outcomes

The 5- and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively (Figure-1A). The log-rank test indicated that bRFS rates for the RP group were lower compared with the LDR group (P=0.003, (Figure-1A). The 5- and 8-year cRFS rates were 94.2% in the RP group, and 95.1% and 93.7% in the LDR group, respectively (Figure-1B). The 5- and 8-year CSS rates were 99.2% in the RP group, and 98.9% in the LDR group (Figure-1C). The 5- and 8-year OS rates were 98.6% and 97.0% in the RP group, and 97.7% and 95.4.5% in the LDR group, respectively (Figure-1D). The log-rank test were not significant for cRFS, CSS or OS rates between RP and LDR groups (cRFS: P=0.404, Figure-1B; CSS: P=0.774, Figure-1C; OS: P=0.951, Figure-1D).
Comparison of bRFS curves between LDR and RP groups under the condition of different variables is shown in Table 2. Log-rank test was used to compare the bRFS curves between LDR and RP in terms of different variables according to pretreatment characteristics. Risk of BF was significantly higher with RP compared with LDR in the patients with GS 7 (3+4: P=0.027; 4+3: P=0.001), prostate volume >30ml (P<0.001), iPSA ≤ 10 ng/ml (P=0.007), clinical T stage with T1c-T2a (P=0.016), any PPBC(≤ 50%: P=0.043; >50%: P=0.003) or unfavorable IRPC(P=0.003). However, survival of LDR patients was not statistically different from RP patients at any age, GS 6, prostate volume ≤30ml, iPSA > 10 ng/ml, clinical T stage with T2b-T2c or favorable IRPC.

**Prognostic Factors**

Cox proportional-hazard models were constructed to identify factors associated with bRFS, and results are shown in Table 3. With univariate analysis of the entire cohort, treatment with RP (P=0.004), age <70 years old (P=0.001) and clinical T stage with T2b-T2c (P=0.005), prostate volume ≤30ml(P<0.001) and PPBC>50% (P<0.001) were associated with significantly worse bRFS. With multivariate analysis of the entire cohort, treatment with RP (P=0.029), prostate volume ≤30ml (P<0.001) and PPBC>50% (P<0.001) were associated with significantly worse bRFS. Treatment with RP was associated with significantly worse bRFS by both univariate analysis (hazard ratio [HR] 0.533, 95% confidence interval [CI] 0.349-0.814; P=0.004) and multivariate analysis (HR 0.589, 95% CI 0.366-0.948; P=0.029).

**Discussion**

Currently the guidelines of the American Urological Association, the European Association of Urology and the NCCN endorse RP, LDR and EBRT therapy as appropriate treatment options for IRPC. No differences have been observed in OS or CSS among the three approaches in the recent studies (14, 15). However, treatment options for Pca are diverse, and therapeutic decisions are largely based on the condition of each medical institution, the preference of doctors and the cognition of patients (14). The comparison of the oncological outcomes of RP and LDR treatments remains a challenge, due to differential definitions for recurrence and methodological biases arising from the differences in baseline characteristics, including age, comorbidity and cancer risk features (14, 16-18). A randomized controlled trial is the ideal approach for comparing competing treatment modalities (19). However, most of the previously reported literatures comparing the efficacy of LDR and RP are retrospective studies (14, 20). Compared with candidates for RP patients who are offered LDR generally tend to be older and have higher comorbidity scores, therefore, a random trial is impractical (17, 18).

We retrospectively analyzed data from 361 IRPC patients treated in our hospital. Our results showed there were no statistically significant differences in the cRFS, CSS and OS between the two therapeutic groups. This result was consistent with recent publications in the literature, though they were not supported by randomized prospective studies (21-23). Hamdy et al reported 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, and there were no significant difference in cRFS, CSS and OS between treatments of surgery and radiotherapy (15). However, his study included patients
of all risk categories, and thus we cannot make any conclusions regarding IRPC. Goy et al statistically analyzed 1503 IRPC patients who underwent treatment from 2004 to 2007. There were no significant differences in cRFS or CSS. The 10-year bRFS was 80.2% for LDR vs 57.1% for RP vs 57.0% for EBRT, which showed improved bRFS with LDR, \( P = 0.0003 \) (24). But LDR patients had a significantly smaller proportion number compared with RP (7.3% Vs 54.5%) in his study, which might cause some bias in the results. In our study, the proportion of patients in both groups was more balanced than that in Goy’s study. Consistent with Goy’s results, in the present study, the 5- and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively. The log-rank test showed the bRFS for RP was significantly lower than LDR. However, in terms of the pretreatment characteristics, patients treated with LDR were older, experienced longer follow-up time, and had a higher preponderance of combined ADT treatment. In previous studies using models adjusted for risk, ADT was not shown to be an independent predictor (18, 25). Our study supports the use of LDR as a reasonable treatment option for IRPC.

Neither treatment modality has proven superior to the other with respect to RP and LDR; therefore, the optimal treatment for different risk categories in Pca remains a matter of debate. Although our median follow-up time of 54 months was sufficient to capture a considerable number of systemic failure events, it may still be too short to achieve mortality results. Therefore, we chose bRFS as the main evaluation criterion of curative effect. We observed that bRFS was significantly higher with LDR than RP in patients with GS 7, prostate volume >30ml, iPSA \( \leq 10 \) ng/ml, clinical T stage with T1c-T2a, any PPBC or unfavorable IRPC. Supported by the results of our study, LDR may be a better option than RP in patients with the above conditions. In our experience, a subgroup analysis of unfavorable IRPC had improved bRFS with LDR compared to RP. These results showed that LDR was also a good option for those with unfavorable IRPC. Taussky et al reported RP and LDR treatment did not result in significantly different outcomes at four years post-treatment in patients with low- and low-intermediate- risk Pca (26). However, Ferreira et al found the 5-year bRFS of patients with early Pca who had undergone LDR was significantly higher than those who had undergone surgery (27). Furthermore, Ciezki et al reported high-risk Pca treated with EBRT, LDR, or RP yields efficacy with better bRFS for LDR and EBRT compared with RP (21). It should be noted that these studies were obviously heterogeneous, because different centers adopted different LDR technologies, and different methods were used to compare the results between RP and LDR (28).

As the previously studies reported, there were many factors affecting the prognosis of Pca, including general situation, tumor stage, tumor grade, iPSA, age and bone scintigraphy (29-31). Ciezki et al found clinical stage T3, GS 8 to 10, higher iPSA and more frequent PSA testing after therapy were all associated with a significantly worse bRFS (21). Taussky et al reported younger age, higher percentage of positive biopsies, and PSA at diagnosis were predictive of BF (26). On univariate analysis of the entire cohort in the present study, treatment with RP, age <70 years old, clinical T stage with T2b-T2c, prostate volume \( \leq 30ml \) and PPBC>50% were associated with significantly worse bRFS. Previous studies had reported that clinical stage was the most dangerous factor influencing Pca prognosis (32, 33). On multivariate analysis
of the entire cohort, treatment with RP, prostate volume \( \leq 30\text{ml} \) and PPBC>50\% were associated with significantly worse bRFS. Therefore, they were important independent prognostic factors.

The limitations of this study include the following: (1) The baseline characteristics of the two groups did not completely match, which was inevitable due to random grouping in a retrospective study. Therefore, a prospective study comparing eligible patients is needed to make a more accurate conclusion. (2) The aim of our study was to provide a guide to aid clinical decision making at diagnosis. Thus, duration of ADT following initial treatment, which may contribute to survival, was not adjusted. However, in previous studies using models adjusted for risk, ADT was not shown to be an independent predictor (18, 25). (3) The definition of BF is different for the RP versus LDR groups. Although this definition is commonly used in the world(15, 23, 24), it could cause some bias in interpretation of the results. (4) There were fewer deaths in this study; therefore, whether higher bRFS rates observed in patients could translate into superior oncological endpoints is still undetermined. A longer observational period is needed for a meaningful comparison of overall survival.

**Conclusions**

In summary, LDR, with or without androgen deprivation, is as good a treatment option for IRPC patients, producing equivalent rates of cRFS, CSS and OS compared with RP. Despite the difference in BF definitions, LDR improved bRFS compared with RP. Treatment with RP (\( P=0.029 \)), prostate volume \( \leq 30\text{ml} \) (\( P<0.001 \)) and PPBC>50\% (\( P<0.001 \)) were independent predictors for worse bRFS. A longer follow-up may be necessary to detect a difference in OS between these two treatments.

**Abbreviations**

ADT: androgen deprivation therapy  
BF: biochemical failure  
bRFS: biochemical relapse-free survival  
cRFS: clinical relapse-free survival  
CI: confidence interval  
CSS: cancer-specific survival  
EBRT: external beam radiation therapy  
GS: Gleason score  
HR: hazard ratio  
iPSA: initial prostate-specific antige
IRPC: intermediate-risk prostate cancer
LDR: low-dose-rate brachytherapy
NCCN: The National Comprehensive Cancer Network
OS: overall survival
Pca: Prostate cancer
PPBC: Percentage positive biopsy cores
PSA: prostate-specific antigen
RP: Radical prostatectomy

Declarations

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) of Peking Union Medical College Hospital (PUMCH). The present study was approved by the Institutional Review Board of Peking Union Medical College Hospital. Informed consent was obtained from all individual participants included in the study.

Consent for publication
Not applicable.

Acknowledgements
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
None.
Authors' contributions

ZEZ, YZ, and WY designed and conceived the research. ZEZ and YZ acquired the data. ZBZ and XW analyzed the data. WY, FZ, ZJ, HL performed critical revision of the manuscript. ZEZ and MH wrote the draft. WY supervised the study. All authors reviewed the manuscript and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016;66(2):115-32.
3. Lancee M, Tikkinen KAO, de Reijke TM, Kataja VV, Aben KKH, Vernooij RWM. Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. BJU international. 2018;122(4):535-48.
4. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology. 2017;71(4):618-29.
5. Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2019;17(5.5):583-6.
6. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. International journal of radiation oncology, biology, physics. 2001;51(1):31-40.
7. Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). International journal of radiation oncology, biology, physics. 2011;81(1):31-40.
8. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. The New England journal of medicine. 2012;367(3):203-13.
9. Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. European urology. 2013;64(6):895-902.
10. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. The Journal of urology. 1998;160(6 Pt 2):2418-24.
11. Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML. Seed fixity in the prostate/periprostatic region following brachytherapy. International journal of radiation oncology, biology, physics. 2000;46(1):215-20.

12. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology. 2007;177(2):540-5.

13. Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International journal of radiation oncology, biology, physics. 2006;65(4):965-74.

14. Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, et al. Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. European urology. 2018;73(1):11-20.

15. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. The New England journal of medicine. 2016;375(15):1415-24.

16. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018;319(9):896-905.

17. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. The Journal of urology. 2012;187(4):1259-65.

18. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226-34.

19. Donovan JL, Lane JA, Peters TJ, Brindle L, Salter E, Gillatt D, et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. Journal of clinical epidemiology. 2009;62(1):29-36.

20. Huang H, Muscatelli S, Naslund M, Badiyan SN, Kaiser A, Siddiqui MM. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. The Journal of urology. 2019;201(1):120-8.

21. Ciezki JP, Weller M, Reddy CA, Kittel J, Singh H, Tendulkar R, et al. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage
Radiation Therapy for High-Risk Prostate Cancer. International journal of radiation oncology, biology, physics. 2017;97(5):962-75.

22. Zhou Z, Yan W, Zhou Y, Zhang F, Li H, Ji Z. (125)I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. Oncology letters. 2019;18(1):72-80.

23. Hayashi N, Osaka K, Muraoka K, Hasumi H, Makiyama K, Kondo K, et al. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. World journal of urology. 2019.

24. Goy BW, Burchette R, Soper MS, Chang T, Cosmatos HA. Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer. Urology. 2020;136:180-9.

25. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute. 2003;95(13):981-9.

26. Taussky D, Ouellet V, Delouya G, Saad F. A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2016;10(7-8):246-50.

27. Ferreira AS, Guerra MR, Lopes HE, Lima UT, Vasconcelos YA, Teixeira MT. Brachytherapy and radical prostatectomy in patients with early prostate cancer. Revista da Associacao Medica Brasileira (1992). 2015;61(5):431-9.

28. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. The New England journal of medicine. 2002;347(11):781-9.

29. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer. 1993;72(12 Suppl):3788-92.

30. Nakashima J, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urologia internationalis. 2008;80(2):129-33.

31. Choi SY, Chi BH, Lim B, Kyung YS, You D, Jeong IG, et al. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer. Journal of cancer research and clinical oncology. 2020;146(2):537-43.

32. Joly F, Henry-Amar M. [Prognostic factors of localised, locally advanced or metastatic prostate cancer]. Bulletin du cancer. 2007;94(7 Suppl):F35-43.

33. Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Japanese journal of clinical oncology. 2003;33(1):1-5.

Tables
| Parameters                      | RP(n=160) | LDR(n=201) | P value |
|--------------------------------|-----------|------------|---------|
| Age (years)                    |           |            | <0.001  |
| Median                         | 66        | 74         |         |
| Range                          | 48-78     | 50-84      |         |
| Clinical Stage                 |           |            | 0.002   |
| T1c                            | 15(9.4%)  | 42         |         |
| T2a                            | 40(25.0%) | 36         |         |
| T2b                            | 41(25.6%) | 32         |         |
| T2c                            | 64        | 91         |         |
| Gleason Score                  |           |            | 0.086   |
| 6(3+3)                         | 75(4)     | 79         |         |
| 7(3+4)                         | 54        | 63         |         |
| 7(4+3)                         | 31        | 59         |         |
| Prostate volume (ml)           |           |            | 0.172   |
| ≤30                            | 76(4)     | 110        |         |
| >30                            | 84        | 91         |         |
| Initial PSA (ng/ml)            |           |            | 0.891   |
| Median                         | 12        | 12.5       |         |
| Range                          | 4.2-20    | 0.8-19.9   |         |
| Risk                           |           |            | 0.172   |
| Favorable                      | 45        | 44         |         |
| Unfavorable                    | 115       | 157        |         |
| PPBC                           |           |            | 0.734   |
| ≤50%                           | 125       | 154        |         |
| >50%                           | 35        | 47         |         |
| Follow-up, months              |           |            | <0.001  |
| Median                         | 54        | 69         |         |
| Range                          | 17-114    | 26-117     |         |
| Duration ADT, months           |           |            | <0.001  |
| 0                              | 110       | 11         |         |
| 1-6                            | 25        | 94         |         |
| ≥6                             | 25        | 96         |         |
Table 2: Comparison of the bRFS curves between LDR and RP groups, according to different variables using a log-rank test.

| Variables               | P value |
|-------------------------|---------|
| Age, years              |         |
| <70                     | 0.328   |
| ≥70                     | 0.117   |
| Gleason score           |         |
| 6(3+3)                  | 0.667   |
| 7(3+4)                  | 0.027   |
| 7(4+3)                  | 0.001   |
| Prostate volume, ml     |         |
| ≤30                     | 0.953   |
| >30                     | <0.001  |
| iPSA, ng/ml             |         |
| ≤10                     | 0.007   |
| 10.1-20                 | 0.085   |
| Clinical T Stage        |         |
| T1c, T2a                | 0.016   |
| T2b, T2c                | 0.065   |
| PPBC                    |         |
| ≤50%                    | 0.043   |
| >50%                    | 0.003   |
| Risk                    |         |
| Favorable               | 0.342   |
| Unfavorable             | 0.003   |
### Table 3 Univariate and multivariable analyses of prognostic factors

| Factor                  | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | P value             | HR (95% CI)           | P value             | HR (95% CI)           |
| Treatment               |                     |                       |                     |                       |
| RP                      | 0.004               | 1                     | 1                   | 0.589 (0.366-0.948)   |
| LDR                     |                     | 0.533 (0.349-0.814)   | 0.029               | 0.589 (0.366-0.948)   |
| Age, years              | 0.001               | 0.497 (0.325-0.761)   | 0.708               | 0.437 (0.1146)        |
| <70                     | 1                   | 1.988 (1.225-3.226)   | 1.296               | 0.764 (2.198)         |
| ≥70                     |                     |                       |                     |                       |
| Clinical T stage        | 1                   | 1                     | 1                   | 0.708 (0.437-1.146)   |
| T1c, T2a                |                     |                       |                     |                       |
| T2b, T2c                | 0.005               | 0.708 (0.437-1.146)   | 0.726               | 0.708 (0.437-1.146)   |
| iPSA, ng/ml             | 1                   | 1                     | 1                   | 0.708 (0.437-1.146)   |
| ≤10                     | 1                   | 1.988 (1.225-3.226)   | 1.296               | 0.764 (2.198)         |
| 10.1-20                 | 0.151               | 0.726 (0.468-1.124)   | -                   | -                     |
| Gleave score            | 1                   | 1                     | 1                   | 0.708 (0.437-1.146)   |
| 6(3+3)                  |                     |                       |                     |                       |
| 7(3+4)                  | 0.523               | 0.856 (0.531-1.380)   | 0.615               | 0.856 (0.531-1.380)   |
| 7(4+3)                  | 0.095               | 0.615 (0.347-1.088)   | 0.615               | 0.615 (0.347-1.088)   |
| Prostate volume, ml     | 1                   | 1.988 (1.225-3.226)   | 1.296               | 0.764 (2.198)         |
| ≤30                     | <0.001              | 0.349 (0.218-0.560)   | <0.001              | 0.398 (0.246-0.643)   |
| >30                     |                     |                       |                     |                       |
| PPBC                    | <0.001              | 2.826 (1.846-4.327)   | <0.001              | 2.440 (1.529-3.896)   |
| ≤50%                    | 1                   | 1                     | 1                   | 2.440 (1.529-3.896)   |
| >50%                    |                     |                       |                     |                       |

**Figures**
Figure 1

Kaplan-Meier survival curves of bRFS (A), cRFS (B), CSS (C) and OS (D) in patients with IRPC treated with LDR vs RP. bRFS biochemical relapse-free survival; cRFS clinical relapse-free survival; CSS cancer specific survival; OS overall survival; IRPC intermediate-risk prostate cancer; LDR low-dose-rate brachytherapy; RP radical prostatectomy.